In this year, the following research findings were presented:
GBG Presentation-Highlights at ESMO Breast Cancer 2026
GBG Poster Highlights at ESMO Breast Cancer 2026
Poster 43P
“Increased lymph node germinal centre circularity is associated with improved invasive disease-free survival in triple-negative breast cancer patients of the GAIN-2 trial”
Presenter: Lucy Ryan
Using the AI-based pathology tool smuLymphNet, this analysis from the GAIN-2 trial demonstrated that higher germinal centre circularity in lymph nodes is associated with improved invasive disease-free and overall survival in early triple-negative breast cancer. The findings highlight the potential of digital pathology and immune-related lymph node features for improved prognostication.
Poster 63P
“Prognostic stratification of breast cancer after neoadjuvant systemic therapy by application of a modified Sinn regression grade”
Presenter: Prof. Aurelia Noske
Based on data from the GeparSepto, GeparOcto, GeparNuevo, and GeparX trials, this study showed that combining tumor regression grading with post-treatment nodal status improves prognostic stratification after neoadjuvant therapy. The modified regression grade may support more precise risk assessment and personalized treatment decisions in breast cancer.
Poster 274P
“Safety and Tolerability of Neoadjuvant Inavolisib Combined with Endocrine Therapy and Dual HER2 Blockade in Early HR+/HER2+/PIK3CA-Mutant Breast Cancer: 2nd preplanned Safety Interim Analysis of the Chemotherapy-free GeparPiPPa Study”
Presenter: PD Dr. Mattea Reinisch
The GeparPiPPa study evaluates a chemotherapy-free treatment approach combining inavolisib, endocrine therapy, and dual HER2 blockade in HR+/HER2+/PIK3CA-mutant early breast cancer. Interim safety results demonstrated a manageable tolerability profile with no unexpected toxicities, supporting the feasibility of biomarker-driven de-escalation strategies.
Poster 78P
“Desmocollin 2 as a Predictive Marker for the Development of Distant Metastasis in Breast Cancer”
Presenter: PD Dr. Elena Laakmann
Analyses from the GeparQuinto and GeparSixto studies identified high Desmocollin 2 (DSC2) expression as being associated with aggressive breast cancer biology, higher proliferation, and poorer outcomes. Although no clear association with CNS metastases was confirmed, DSC2 may serve as a promising biomarker for risk stratification in breast cancer.konnte, zeigt DSC2 Potenzial als prognostischer Biomarker zur Risikostratifizierung bei Brustkrebs.
